JHD205, A Novel Abemaciclib Derivative, Exerts Antitumor Effects on Breast Cancer by CDK4/6

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype requiring novel therapeutics.
• Current treatment options for TNBC are limited, highlighting the need for targeted molecular therapies.

Purpose of the Study:

• To investigate the efficacy of selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitors for TNBC treatment.
• To evaluate a novel compound, JHD205, as a potential therapeutic agent for TNBC.

Main Methods:

• Synthesis of JHD205, a derivative of Abemaciclib.
• Assessment of JHD205's effects on TNBC cell proliferation and survival in preclinical models.
• Western blot analysis to determine the molecular mechanisms of JHD205 action.

Main Results:

• JHD205 demonstrated superior tumor growth inhibition compared to Abemaciclib in breast cancer xenograft models.
• JHD205 dose-dependently degraded CDK4 and CDK6, impacting key cell cycle regulators (p-Rb, Rb, E2F1).
• JHD205 induced apoptosis and DNA damage, while inhibiting DNA repair pathways (upregulating Caspase3 and p-H2AX).

Conclusions:

• JHD205 exhibits significant anti-cancer activity against TNBC.
• The findings support JHD205 as a promising candidate for the treatment of breast carcinoma.